Medication classes
IL-23 inhibitor articles covering treatments such as risankizumab and other therapy updates relevant to Crohn's disease and IBD.
Page 2 of 5 · 226 articles
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from seekingalpha.com.
Long-term control of symptoms and intestinal inflammation is a major need in Crohn's disease. Three-year data showing sustained clinical and endoscopic remission and high rates of steroid-free remission could be...
Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
Long-term (3-year) data on a biologic for Crohn's disease may indicate how durable treatment benefits and steroid-free remission can be for people considering or already on biologic therapy.
Perianal fistulas are a common and debilitating complication of Crohn’s disease that often need medical and surgical care. A Phase 3 trial reporting improved fistula remission with an IL-23–targeting therapy could offer...
Patients and clinicians may see continued availability and promotion of Skyrizi and Rinvoq across IBD indications, which can affect prescribing options and market competition. Sales growth and approvals also influence...
Long-term control of inflammation and healing of draining fistulas are important for people with Crohn’s disease; these FORTIFY OLE analyses suggest durable benefit with risankizumab in responders through several years...
New long‑term and real‑world data for risankizumab and upadacitinib were presented at ACG 2026, which may influence treatment considerations for people with difficult‑to‑treat Crohn's disease and ulcerative colitis.
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
Adherence affects how well advanced IBD treatments work. Knowing which drug forms and patient factors link to missed doses can help patients and clinicians plan support strategies.
This study suggests mirikizumab can maintain endoscopic and symptomatic improvements for up to two years in many patients with Crohn’s disease, and that IV reinduction can recover response in a subset of 1-year...
The analysis suggests that some biologic and small-molecule therapies work differently depending on whether Crohn's disease affects the ileum, colon, or both — information that could help tailor long-term treatment...
Perianal fistulas cause significant morbidity and often need both medical and surgical treatments. Newer drug options and updated guideline support earlier use of advanced therapies, which may improve healing and reduce...
Perianal fistulizing Crohn's often causes significant symptoms and requires both medical and surgical approaches. Newer biologics and JAK inhibitors expand treatment options and guidelines increasingly support earlier...
If true, the tripartite circuit model helps explain why some patients respond to therapies that target one pathway while others do not — because other nodes in the loop may sustain disease.
This registry will collect real-world data on guselkumab use in adults with moderate-to-severe Crohn's disease or ulcerative colitis, focusing on how long patients stay on treatment, effectiveness in routine practice,...
A single‑patient report suggests guselkumab (IL‑23 inhibitor) may control both refractory pyoderma gangrenosum and coexisting Crohn disease when several prior treatments failed.
This case series points to risankizumab as a potential option for children with IBD who have failed multiple biologics, and it reports use of noninvasive monitoring like intestinal ultrasound.
Mirikizumab showed higher rates of clinical and endoscopic remission than placebo in pooled randomized trials, which could expand treatment options for people with moderate-to-severe ulcerative colitis if confirmed by...
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
This trial tests several targeted therapies (including risankizumab) alone and in combination for adults with moderate to severe Crohn's disease, aiming to measure endoscopic remission and safety. Positive findings could...
IL-23 inhibitors are a newer class of biologics for moderate-to-severe ulcerative colitis that may offer another effective option for patients who have not responded to existing therapies, with improving evidence for...
Orofacial granulomatosis often co-occurs with Crohn's disease and appears linked to a distinct Crohn's phenotype and treatment needs. The findings suggest that advanced therapies can be effective for OFG-associated CD...
Researchers are testing whether blocking three inflammation pathways at once can reduce tissue inflammation more than single drugs. If ex vivo results show stronger effects, it could guide development of multi-target...
PG is a serious skin complication that can occur with UC. This report suggests guselkumab—an IL‑23 blocker used in IBD and dermatology—helped resolve PG in one patient without loss of UC remission, which could be...
Based on the title and source metadata, this appears to be a systematic review or meta analysis related to Inflammatory bowel disease, Guselkumab, and IL-23 inhibitor. The original article is from Journal of clinical...
This trial is testing risankizumab in children with moderate-to-severe Crohn’s disease to learn how the drug behaves in kids, whether it’s safe, and whether it reduces disease activity — information that could expand...
This article explains why two widely used IBD drugs from AbbVie (Skyrizi and Rinvoq) are central to the company’s growth and describes ongoing development efforts that could expand treatment options and indications in...
Real-world 52-week data suggest mirikizumab can produce meaningful remission and reasonable drug persistence in patients with treatment-experienced ulcerative colitis. This is especially relevant for people who have not...
Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...
For people with multi-refractory Crohn’s disease or ulcerative colitis, adding a JAK inhibitor to an existing biologic (advanced combination therapy) may convert partial responses into deeper remission in selected cases,...
Psoriasis and Crohn’s disease share immune pathways that affect treatment choices. Some biologics work across both conditions while others (notably IL-17 inhibitors) may be inappropriate for patients with active IBD.
A new IL-17A drug (vunakizumab) is reported to have triggered severe ulcerative colitis in one patient, suggesting clinicians and patients starting IL-17A inhibitors should watch for early gastrointestinal symptoms.
Market and late-stage trial updates can indicate which new therapies may become available and influence treatment options, access, and research priorities for Crohn's disease over the coming years.
People with IBD who don’t respond well to ustekinumab may need alternative options. This study will track how patients fare after switching to guselkumab in routine clinical care and report rates of deep remission at one...
A systematic review finds risankizumab (an IL-23 inhibitor) effective and generally well tolerated for moderate-to-severe Crohn's disease and ulcerative colitis, including in patients who failed prior biologics. This...
Phase 3 testing of guselkumab (an IL-23–targeting biologic) in moderately to severely active ulcerative colitis could expand treatment options if the trial meets its endpoints and shows an acceptable safety profile. The...
A new subcutaneous induction option for risankizumab could make starting this biologic easier for many adults with moderate-to-severe Crohn's disease by avoiding infusions, potentially increasing access and convenience.
Cure8 found this source from marketscreener.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full...
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from tradingview.com.
A subcutaneous induction option could make starting risankizumab easier and less burdensome than IV infusions for many people with Crohn's disease, potentially expanding access and convenience.
A new subcutaneous induction option for risankizumab could make starting IL‑23 therapy more convenient for adults with moderately to severely active Crohn’s disease and expand choices for those who have failed prior...
If approved, a subcutaneous induction option for risankizumab would let eligible adults start and continue treatment without needing an infusion visit, which can be more convenient and reduce infusion-related costs and...
Patients, clinicians, and payers may care because the analysis addresses the relative economic value of two approved biologic options (vedolizumab and risankizumab) for Crohn’s disease treatment in Italy and could...
Perianal fistulas are a serious, common complication of Crohn's disease that are often difficult to heal. This study tests a real-world combination of surgery plus an approved IL-23 inhibitor (mirikizumab) to see if...
Comparative real-world data may help patients and clinicians weigh expected benefits and risks of risankizumab versus ustekinumab in Crohn’s disease, including effects on steroid-free remission and fistula healing.
Pharmacokinetics affect how well biologic drugs work for IBD. Better PK data could help explain why many patients have inadequate responses and could inform personalized dosing for IL-23p19 inhibitors used in Crohn’s...
Researchers are testing whether targeting fungi with fluconazole can boost how well IL-23 biologics work for Crohn’s disease — if positive, this could point to a new adjunctive strategy to improve responses to biologic...
